Crinetics Pharmaceuticals, Inc.
Here’s whether Crinetics Pharmaceuticals, Inc. (CRNX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+21.93% over 10 days); strong 1-year return of +175.3%; 3-month momentum positive (+118.5%). Concerns: RSI 99 — overbought, elevated pullback risk; declining volume on rally — weak conviction (0.67x 30d avg). Currently 0.3% off its 52-week high. Score: +4/7.
CRNX is in a confirmed uptrend, trading above both its 50-day ($49.33) and 200-day ($45.04) moving averages. With an RSI of 99.1, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +175.3% compares to +16.5% for SPY (beat the market by 158.9%).